文献速递胸部肿瘤

MALAT1诱导HCC827肺癌细胞奥希替尼耐药的机制

[Mechanism of MALAT1 induced osimertinib resistance in HCC827 lung cancer cells].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2019-01-01

在HCC827肺癌细胞中过表达MALAT1后,奥希替尼的半数抑制浓度>4000 nmol/L,提示耐药;敲减ERBB3后奥希替尼的半数抑制浓度降至(17.27±3.21) nmol/L,10 nmol/L奥希替尼诱导的凋亡率由(8.38±0.92)%升至(27.17±5.83)%(P<0.01)。MALAT1可能通过激活ERBB3/PI3K/AKT和ERBB3/MAPK/ERK信号通路介导奥希替尼耐药。

要点

  • 过表达MALAT1的HCC827细胞对奥希替尼的半数抑制浓度>4000 nmol/L。
  • 敲减ERBB3后奥希替尼半数抑制浓度为(17.27±3.21) nmol/L。
  • 10 nmol/L奥希替尼凋亡率:过表达MALAT1组(8.38±0.92)% vs 敲减ERBB3组(27.17±5.83)%,P<0.01。

核心结论

  • MALAT1可能通过激活ERBB3/PI3K/AKT和ERBB3/MAPK/ERK信号通路介导HCC827细胞对奥希替尼耐药。

研究设计与样本

  • 体外细胞研究:以LV-vector或LV-over/MALAT1转染HCC827细胞,经嘌呤霉素筛选建立稳定细胞株HCC827/Vector和HCC827/MALAT1。
  • HCC827/MALAT1细胞进一步转染shRNA阴性对照或shRNA-ERBB3,用MTT法检测增殖、流式细胞术检测凋亡、Western blot检测EGFR和ERBB3信号通路相关蛋白。

主要发现

  • MTT显示奥希替尼对HCC827/MALAT1细胞增殖的抑制作用显著降低,半数抑制浓度>4000 nmol/L。
  • 干扰ERBB3后HCC827/MALAT1细胞对奥希替尼再次敏感,半数抑制浓度为(17.27±3.21) nmol/L。
  • 10 nmol/L奥希替尼干预后,HCC827/MALAT1细胞凋亡率为(8.38±0.92)%,低于干扰ERBB3后的(27.17±5.83)%,差异有统计学意义(P<0.01)。
  • Western blot显示HCC827/MALAT1细胞中p-ERBB3、p-AKT和p-ERK蛋白明显上调,p-EGFR表达受抑制。
  • 奥希替尼对HCC827/MALAT1细胞的p-ERBB3、p-AKT和p-ERK表达无影响;敲减ERBB3后奥希替尼下调p-EGFR、p-ERBB3、p-AKT和p-ERK表达水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To test the effect of metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) and/or osimertinib on the proliferation and apoptosis of HCC827 cells, and explore the potential mechanism of MALAT1 induced resistance to osimertinib. Methods: We transfected HCC827 cells with LV-vector or LV-over/MALAT1. Stable transfected cells (HCC827/Vector, HCC827/MALAT1) were selected by adding puromycin. HCC827/MALAT1 cells were further transfected with the shRNA-negative control (NC) or shRNA-human epidermal growth factor receptor 3 (ERBB3) plasmid. The effects of overexpression of MALAT1, knockdown of ERBB3 and/or osimertinib on the proliferation of HCC827 cells were evaluated by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H tetrazolium bromide (MTT) assay. Cell apoptosis induced by MALAT1 overexpression, knockdown of ERBB3 and/or osimertinib treatment were analyzed by flow cytometry analysis. The expressions of EGFR and ERBB3 signal pathway related proteins in HCC827 cells treated with overexpression of MALAT1, knockdown of ERBB3 and/or osimertinib treatment were detected by western blot. Results: The MTT assay showed that sensitivity to osimertinib of HCC827/MALAT1 cells were significantly repressed. The 50% inhibitive concentration (IC(50)) of osimertinib >4 000 nmol/L in HCC827/MALAT1 cells. However, knockdown of ERBB3 facilitated the anti-proliferation effect of osimertinib, and the IC(50) of osimertinib in shRNA-ERBB3 cells was (17.27±3.21) nmol/L. The results of flow cytometry analysis showed that the apoptotic rate of HCC827/MALAT1 cells induced by 10 nmol/L osimertinib was (8.38±0.92)%, significantly lower than (27.17±5.83)% of knockdown of ERBB3 (P<0.01). Western blotting showed that the expression of p-ERBB3, p-AKT and p-extracellular regulated protein kinases (ERK) in HCC827/MALAT1 cells was markedly up-regulated, while the expression of p-epithelial growth factor receptor (EGFR) was inhibited. The expressions of p-ERBB3, p-AKT and p-ERK were marginally affected by osimertinb. However, osimertinib downregulated the expressions of p-EGFR, p-ERBB3, p-AKT and p-ERK in ERBB3 deleted cells. Conclusions: MALAT1 confers resistance to osimertinb in HCC827 cells by activating of the ERBB3/PI3K/AKT and ERBB3/MAPK/ERK signaling pathways. 目的: 探讨肺腺癌转移相关转录本1(MALAT1)和奥希替尼对肺癌细胞HCC827增殖和凋亡的影响以及MALAT1介导奥希替尼耐药的机制。 方法: 应用LV-vector和LV-over/MALAT1转染HCC827细胞,建立稳定细胞株HCC827/Vector和HCC827/MALAT1。应用短发夹RNA阴性对照(shRNA-NC)、shRNA人表皮生长因子受体3(shRNA-ERBB3)转染HCC827/MALAT1细胞,应用四甲基偶氮唑蓝(MTT)法检测MALAT1、奥希替尼和shRNA-ERBB3对细胞增殖的影响,应用流式细胞术检测MALAT1、奥希替尼和shRNA-ERBB3对细胞凋亡的影响。应用Western blot检测MALAT1、奥希替尼和shRNA-ERBB3作用后,肺癌细胞中表皮生长因子受体(EGFR)和ERBB3信号通路相关蛋白的表达。 结果: MTT结果显示,奥希替尼对HCC827/MALAT1细胞增殖的抑制作用显著降低,半数抑制浓度(IC(50))>4 000 nmol/L;但干扰ERBB3后,HCC827/MALAT1细胞对奥希替尼再次敏感,IC(50)为(17.27±3.21)nmol/L。细胞凋亡实验显示,10 nmol/L奥希替尼干预HCC827/MALAT1细胞后,凋亡率为(8.38±0.92)%;但干扰ERBB3后,奥希替尼能促进HCC827/MALAT1细胞凋亡,凋亡率为(27.17±5.83)%,差异有统计学意义(P<0.01);Western blot检测结果显示,HCC827/MALAT1细胞中磷酸化ERBB3(p-ERBB3)、p-AKT和p-ERK蛋白明显上调,奥希替尼能抑制磷酸化EGFR(p-EGFR)蛋白的表达,但对p-ERBB3、p-AKT和p-ERK蛋白的表达无影响。敲减ERBB3后,奥希替尼能下调p-EGFR、p-ERBB3、p-AKT和p-ERK蛋白的表达水平。 结论: MALAT1可能是通过激活ERBB3/PI3K/AKT和ERBB3/MAPK/ERK信号通路介导了奥希替尼耐药。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Kang XH, Gao YY, Wang Y, et al. [Mechanism of MALAT1 induced osimertinib resistance in HCC827 lung cancer cells]. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31014050. doi:10.3760/cma.j.issn.0253-3766.2019.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。